KEGG   VARIANT: 2261v2
Entry
2261v2                      Variant                                
Name
FGFR3 erdafitinib-susceptible variation
Gene
FGFR3  fibroblast growth factor receptor 3 [KO:K05094]
Organism
hsa_var Human gene variants (Homo sapiens)
Variation
FGFR3-TACC3 fusion, translocation t(4;4)(q16;q16)
Variation
FGFR3-BAIAP2L1 fusion, translocation t(4;7)(p16;q22)
Network
nt06210  ERK signaling (cancer)
nt06265  Bladder cancer
nt06526  MAPK signaling
Disease
H00022  Bladder cancer
Drug target
Erdafitinib: D10927<US>
Reference
  Authors
Marandino L, Raggi D, Giannatempo P, Fare E, Necchi A
  Title
Erdafitinib for the treatment of urothelial cancer.
  Journal
Expert Rev Anticancer Ther 19:835-846 (2019)
DOI:10.1080/14737140.2019.1671190
Reference
  Authors
Nadal R, Bellmunt J
  Title
Management of metastatic bladder cancer.
  Journal
Cancer Treat Rev 76:10-21 (2019)
DOI:10.1016/j.ctrv.2019.04.002
LinkDB

DBGET integrated database retrieval system